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Abstract
Background: Beclin 1, an important autophagy-related protein in human cells, is involved in cell death and cell
survival. Beclin 1 mapped to human chromosome 17q21. It is widely expressed in normal mammary epithelial cells.
Although down-regulated expression with mono-allelic deletions of beclin 1 gene was frequently observed in
breast tumors, whether there was other regulatory mechanism of beclin 1 was to be investigated. We studied the
expression of beclin 1 and explored the possible regulatory mechanisms on its expression in breast tumors.
Methods: 20 pairs of tumors and adjacent normal tissues from patients with sporadic breast invasive ductal cancer
(IDCs) were collected. The mRNA expression of beclin 1 was detected by real-time quantitative RT-PCR. Loss of
heterozygosity (LOH) was determined by real-time quantitative PCR and microsatellite methods. The protein
expression of beclin 1, p53, BRCA1 and BRCA2 was assessed by immunohistochemistry. CpG islands in 5' genomic
region of beclin 1 gene were identified using MethylPrimer Program. Sodium bisulfite sequencing was used in
examining the methylation status of each CpG island.
Results: Decreased beclin 1 mRNA expression was detected in 70% of the breast tumors, and the protein levels
were co-related to the mRNA levels. Expression of beclin 1 mRNA was demonstrated to be much higher in the
BRCA1 positive tumors than that in the BRCA1 negative ones. Loss of heterozygosity was detected in more than
45% of the breast tumors, and a dense cluster of CpG islands was found from the 5' end to the intron 2 of the
beclin 1 gene. Methylation analysis showed that the promoter and the intron 2 of beclin 1 were aberrantly
methylated in the tumors with decreased expression.
Conclusions: These data indicated that LOH and aberrant DNA methylation might be the possible reasons of the
decreased expression of beclin 1 in the breast tumors. The findings here shed some new light on the regulatory
mechanisms of beclin 1 in breast cancer.
Background
Autophagy is a process of cellular protein degradation
through the autophagosomic-lysosomal pathway, which
plays an important role in cell differentiation and main-
tenance of cellular homeostasis. However, it is usually
defective in tumor cells [1,2]. Beclin 1, the mammalian
orthologue of the yeast Atg6/Vps30 gene, is the first
identified tumor suppressor gene in human to mediate
autophagy [3,4]. It was originally isolated by a yeast-
two-hybrid screen and its protein was identified as an
interacting partner of Bcl-2, an important anti-apoptosis
protein [5]. Beclin 1 has a regulatory role in the process
of vesicle nucleation of autophagy [5,6]. Previous studies
demonstrated that over-expression of beclin 1 induced
apoptosis via activation of caspase-9 in gastric cancer
cells [7], while partial silencing of beclin 1 aggravated
apoptosis in hepatic cancer cells [8]. The different
effects of beclin 1 on cell death and cell survival in dif-
ferent cells depend on the cellular context.
Beclin 1 was mapped to a tumor susceptibility locus
approximately 150 kb centromeric to BRCA1 on human
chromosome 17q21 [9]. Allelic loss of chromosome
17q21 is often found in human prostate, breast and
ovarian cancer [10-13]. Beclin 1 encodes an evolutiona-
rily conserved 60 kDa coiled coil protein that is widely
expressed in human normal adult tissues [9]. It has
been reported that reduced levels of beclin 1 expression
and mono-allelic deletion were observed in human
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are other mechanisms for the loss of beclin 1 expression
in breast cancer remains to be determined.
DNA methylation is the major epigenetic modification
that involves alterations of chromatin structure. There
are increasing evidences that aberrant methylation of
CpG islands in 5' regulatory region of tumor suppressor
gene leads to transcriptional silencing in cancer [14-16].
The human beclin 1 gene contains a 1.5 kb CpG island
from the promoter to part of the intron 2, suggesting
that DNA methylation may be responsible for down-
regulation of beclin 1 expression in cancer. In addition,
the promoter-associated CpG island of beclin 1 contains
E2F target site and four putative consensus Sp1 binding
sites [17]. In the present study, we detected the mRNA
and protein expression levels of beclin 1 and explored
the possible effects of DNA methylation and LOH on
decreased gene expression in breast cancer tissues. The
results here provided some new insights into the regula-
tion of beclin 1 in breast cancer.
Methods
Tissue samples
20 pairs of tumors and adjacent normal tissues from
newly diagnosed patients with sporadic breast invasive
ductal cancer (IDCs) were collected from the First
Affiliated Hospital of China Medical University after the
approval of Institutional Review Board and patients'
informed consents. All the patients were females with-
out family hereditary breast cancer. Radio and chemo
therapy was not applied to the patients before surgical
operation. The patients were consecutive cases. The
median age of these patients was 48.5 year-old (range,
40 - 74). The clinicopathologic parameters, including
patient’sa g e ,t u m o rs i z e ,t u m o rg r a d e ,l y m p hn o d es t a -
tus, estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor-type 2
(HER2) immunoreactivity were obtained from clinical
records. The tissues were obtained after surgical resec-
tion and subsequently microdissected with the assistance
of pathologists. The corresponding adjacent normal tis-
sues were derived from sites adjacent at least 1 cm away
from the tumors. Tissues for immunohistochemistry use
were fixed in 10% buffered formalin, embedded in paraf-
fin, and sectioned with a microtome. Sections were
stained with hematoxylin and eosin for histological
examination by at least two pathologists. Tissue frag-
ments were immediately frozen and stored in liquid
nitrogen till used.
RNA extraction and quantitative reverse transcription PCR
Total RNA from tissues was extracted using TRIZOL
reagent (Invitrogen) according to the manufacture’s pro-
tocol. The first strand cDNA was obtained from total
RNA (0.5 μg) and oligo (dT) using the Reverse Tran-
scription System (Promega). For real-time quantitative
RT-PCR, gene specific primers and TaqMan fluorescent
hybridization probes were used. b-actin was used to
normalize the quantity of specific mRNA. The
sequences of beclin1 and b-actin primers are listed in
Table 1. The PCR product was 85 bp for beclin1 and
295 bp for b-actin. Their authenticity was confirmed by
DNA sequencing. The amplification efficiency deter-
mined for both target and housekeeping genes was
equal. Relative expression levels were calculated by the
2
-ΔΔCt method [18]. Each assay was done in triplicate.
Genomic DNA extraction and quantitative PCR
Genomic DNA of tumors and matched adjacent normal
tissues was extracted with the Dneasy Tissue Kit (Qia-
gen). A Taqman-based quantitative PCR method using
PRISM 7300 Real-Time PCR Thermal Cycler (Applied
Biosystem) was applied to detect the relative copy num-
ber of beclin 1. DNA content per haploid genome was
normalized to that of 18S rDNA and calculated by the
2
-ΔΔCt method [18]. Table 1 showed the sequences of
the specific primer pairs and the Taqman probes. PCR
products were sequenced to confirm their authenticity.
Each assay was done in triplicate. A dilution series was
performed to quantify primer efficiency.
Mutational and microsatellite analysis
To search for mutations of the beclin 1 gene by poly-
merase chain reaction - single strand conformation
polymorphism (PCR-SSCP) analysis, each of the 12
exons was amplified using its specific primers. The
sequences of the primers and PCR conditions were as
described by Aita et al [9]. Denatured PCR products
were loaded onto non-denaturing 6% polyacrylamide
gels, electrophoresed at 4°C, stained with silver staining,
and visualized.
To analyze LOH of the beclin 1 gene, a microsatellite
marker on 17q21, D17S579, was selected through
UniSTS database of National Center for Biotechnology
Information (NCBI). Primer sequences are shown in
Table 1. We defined LOH as a completely absent or sig-
nificantly decreased signal intensity of one allele.
Sodium bisulfite modification and sequencing
The methylation status of the Beclin 1 CpG island was
determined by the bisulfite sequencing method [19].
0.5~1 μg genomic DNA was digested with BamHI that
does not cut within the sequence of the CpG island.
DNA was denatured by 0.3 M NaOH at 42°C for 30
min. Then 3 M sodium bisulfite (Sigma) and 10 mmol/L
hydroquinone were added, which was further incubated
at 50°C for 16 h. Modified DNA was purified using
Wizard DNA purification resin (Promega), re-treated
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ethanol, and resuspended in 50 μL water. Semi-nested
or nested PCR was used to amplify these regions. Primer
sequences are detailed in Table 1. Five clones of each
PCR sample were picked up and sequenced.
Immunohistochemistry
Protein expression of beclin 1 was performed on breast
tissues fixed by formalin and embedded by paraffin.
Slides of 4 μm sections were deparaffinized with xylene
and antigen retrieval was accomplished by heat. The
sections were then incubated in 3% hydrogen peroxide
at room temperature for 5 min to block endogenous
peroxidase activity. Slides were then incubated with rab-
bit anti-beclin 1 polyclonal antibody (Cell Signaling) at
1:300 dilutions at 4°C overnight. Then rinse the slides
three times in PBS for 5 m each and incubate in biotin-
labeled rabbit anti-rabbit secondary antibodies for 1 h
at room temperature. After washing three times
with PBS, the staining was performed using 3, 3'-
diaminobenzidine. Sections were counterstained with
hematoxylin. Staining was considered positive when
cytoplasmic staining was observed in at least 30% of the
neoplastic cells. And staining intensity was the strength
of the signal and was evaluated on a scale of 0 to 2: 0,
negative; 1+, weak staining; 2+, moderate/strong stain-
ing. We also compared IHC data between tumors and
corresponding adjacent normal tissues by percentage of
positive cells and intensity of staining to estimate the
changes of beclin 1 expression.
P53 protein expression was performed using anti-p53
monoclonal antibody (Ab-8, Lab Vision Corporation),
which recognized both wild type and mutant forms of
the p53 protein. BRCA1 and BRCA2 protein expression
were assessed using an anti-BRCA1 monoclonal anti-
body (Ab-1, Oncogene Research Products) and an anti-
BRCA2 polyclonal antibody (Ab-2, Oncogene Research
Products). Samples were considered positive when 20%,
10%, and 10% of the cells were stained with p53,
BRCA1 and BRCA2, respectively.
Table 1 Nucleotide sequences of primers used
Name Sequence (5'®3') Purpose
Bl-F TGCAACCTTCCACATCT RT-PCR
Bl-R TTCCACGGGAACACTG RT-PCR
b-actin-F TCACCCACACTGTGCCCATCTACGA RT-PCR
b-actin-R CAGCGGAACCGCTCATTGCCAATGG RT-PCR
Bl-QF TCTGCCTTCCTCTGTAG Q-PCR
Bl-QR TTCCACGGGAACACTG Q-PCR
18S-QF ACATCCAAGGAAGGCAGCAG Q-PCR
18S-QR TTCGTCACTACCTCCCCGG Q-PCR
Bl-Taqman FAM-CACAGTGGACAGTTTGGCACAATCA-TAMRA Q-PCR
b-actin-Taqman FAM-CAGCCGTGGCCATCTCTTGCTCGAA-TAMRA Q-PCR
18S-Taqman FAM-CGCGCAAATTACCCACTCCCGA-TAMRA Q-PCR
Bl-bs1F GTTTTTTAAAGTGTTGGAATTATAAG Bisulfite first PCR
Bl-bs1R AACTCCTAATCCACAAACTCACAA Bisulfite first PCR
Bl-bs1F’ TTGTTGTTGTTTTGAGATGGAGTT Bisulfite nested PCR
Bl-bs1R’ AAAAATATAAAAACCAAAACC Bisulfite nested PCR
Bl-bs2F GGGTTTGTGAGTTTGTGGATTAG Bisulfite first PCR
Bl-bs2R AAAAAAAACTCCAATAAAAACC Bisulfite first PCR
Bl-bs2F’ AGTTTGTGGATTAGGAGTTTTTGTT Bisulfite nested PCR
Bl-bs2R’ TAAAAATTCCCAAACTCCCTTCTA Bisulfite nested PCR
Bl-bs3F ATTTTAGAAGGGAGTTTGGGAATT Bisulfite first PCR
Bl-bs3R TTAAACCCTTCCATCCCTAAAAC Bisulfite first PCR
Bl-bs3F’ TTTTGGGTTTTAAATTGTTTTTGTT Bisulfite semi-nested PCR
Bl-bs3R’ TTAAACCCTTCCATCCCTAAAAC Bisulfite semi-nested PCR
Bl-bs4F ATATTGTGGATTTTTGAGAGTTTTT Bisulfite first PCR
Bl-bs4R AAATCTTTCTTTTACTACTAAAAACTCTCT Bisulfite first PCR
Bl-bs4F’ TTGTAATTTTAGTATTTTGGGAGAT Bisulfite nested PCR
Bl-bs4R CTCTATTACCCAAACTAAAATACAATAATA Bisulfite nested PCR
D17S579F AGTCCTGTAGACAAAACCTG Microsatellite analysis
D17S579R CAGTTTCATACCAAGTTCCT Microsatellite analysis
Q-PCR, quantitative PCR.
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Data were expressed as mean ± standard deviation. The
ratio of beclin 1 mRNA expression in the tumor to that
in the corresponding adjacent normal tissue in each
case was transformed using a common logarithm. For
statistical comparisons of these log-transformed data
between two groups, a t-test was used. All statistical
analyses were performed using SPSS software, version
10.0 (SPSS Japan Inc., Tokyo, Japan). For all of the sta-
tistical tests, a two-sided p-value of less than 0.05 was
considered statistically significant.
Results
Down-regulated beclin 1 mRNA expression in breast
cancer tissues
We detected relative mRNA expression of beclin 1 of 20
breast tumor tissues vs. corresponding normal tissues by
quantitative RT-PCR. The mean ± SD beclin 1/b-actin
mRNA level was 1.56 ± 1.01 for tumor tissues and 2.24
± 1.39 for adjacent normal tissues (Table 2). As a whole,
down-regulated expression of beclin 1 was found in 14
o u to f2 0( 7 0 % )o ft h eb r e a s tc a n c e rt i s s u e s( F i g u r e1 ) .
Furthermore, 6 out of 20 (30%) in the breast tumors
showed a significant decrease (tumor: normal tissue
ratio < 0.5) of beclin 1 mRNA expression. Meanwhile,
down-regulated beclin 1 mRNA expression was not
observed in 6 out of 20 (30%) of the breast tumors com-
pared to the corresponding normal tissues.
As was shown in Table 3, we analyzed the correlation
between beclin 1 mRNA expression and clinicopatholo-
gical parameters, including age, the presence of lympha-
tic invasion, estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor
receptor-type 2 (HER2). No detectable significant differ-
ence was observed.
Immunohistochemical analysis of beclin 1 protein
expression in breast tumors
Sections of breast tumors were applied to analyze the pro-
tein expression of beclin 1. The staining was cytoplasmic.
13 out of 20 (65%) of tumors showed reduced beclin
1 staining (Figure 2C, 2D) and normal epithelial
cells showed strong cytoplasmic beclin 1 expression
(Figure 2A). As illustrated in Table 4, there was significant
positive correlation between beclin 1 mRNA expression
and immunoreactivity in breast tumors (p < 0.001).
The correlation between beclin 1 mRNA expression and
p53, BRCA1 and BRCA2 protein expression in breast
tumors
P53 protein over-expression was detected in 2 (10%) out
of 20 breast tumors (Figure 3A, Table 5). There was no
obvious excess nuclear p53 protein staining in the corre-
sponding normal tissues, which indicates that the p53
level in the normal tissues is low (Figure 3B). BRCA1
and BRCA2 positive nuclear staining was observed in 6
(30%) and 9 (45%) out of 20 breast tumors, respectively
(Figure 3B, 3D, Table 5). Beclin 1 mRNA levels were
significantly higher in the BRCA1 positive tumors than
those in the BRCA1 negative ones (p = 0.014) (Table 6).
Table 2 Beclin 1/b-actin mRNA expression in breast
tissues
n = 20 Beclin 1/b-actin mRNA expression
Adjacent normal tissues 2.24 ± 1.39
Tumors 1.56 ± 1.01
p = 0.034
Data are means ± SD. The numbers show the mean values of beclin 1/b-actin
mRNA expression and standard deviation in 20 breast tumors and adjacent
normal tissues. Statistical analysis was done by paired t – test.
Figure 1 Beclin 1 mRNA relative expression of breast tumors vs adjacent normal tissues. Quantitative RT-PCR was carried out to detect
the expression of beclin 1 with b-actin as an normalizer.
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Case number Average of log T/N Standard deviation of log T/N P-value
Age (y)
50 11 -0.13 0.06 0.160
≥50 9 -0.30 0.07
Lymphatic invasion
Positive 8 -0.23 0.06 0.356
Negative 11 -0.13 0.05
ER
Positive 7 -0.31 0.08 0.199
Negative 13 -0.15 0.06
PR
Positive 10 -0.20 0.06 0.905
Negative 10 -0.21 0.09
HER2
Positive 19 -0.21 0.07 -
Negative 1 -0.07 -
T, tumors; N, normal tissues; -, not applied.
Figure 2 Immunohistochemical analysis of beclin 1 expression in breast tissues. Photographs were taken at × 200 magnification. A brown
color represents positive staining of beclin 1. Counterstaining of nuclei was performed with hematoxylin as a blue color. (A) Positive staining of
beclin 1 in adjacent normal breast epithelial cells; (B) Positive staining of beclin 1 in a breast tumor; (C) Weak immunoreactivity of beclin 1 in a
breast tumor; (D) Negative control of beclin 1 staining in a breast tumor.
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cancer tissues
Using quantitative PCR method, beclin 1 gene copy
number was detected in all breast tissues. As was shown
in Table 5, LOH was found in 11 out of 20 (55%) of
breast tumors (tumor/normal < 1.0). Meanwhile, we
applied a microsatellite marker, D17S579 [10], to vali-
date the sensitivity of this methodology. LOH was veri-
fied in 9 out of 20 (45%) of breast tumors (Figure 4,
Table 5). Table 7 compared the correlation between
both methods for LOH analysis. The results showed a
significant relationship (p < 0.001) between both meth-
ods, which exhibited accordance in 90% of cases.
CpG island analysis in beclin 1 regulatory region
Previous studiesr e p o r t e dt h a tbeclin 1 maps to 17q21
that spans over 12 kb locus of human genome
( F i g u r e5 A )[ 9 ] .T h e7 0k br e g i o no fg e n o m ei nw h i c h
the beclin 1 gene residues, contains a moderate number
of genes (Figure 5B). Telomerically flanking the beclin
1 gene is the PSME3 gene, a member of the PA28
family, which binds specifically to 20 S proteosomes
and stimulates the hydrolysis of peptides [20], and the
AOC2 gene, a member of the copper-binding amine
oxidase super family, which is an important regulator
of cellular polyamine levels [21]. Centromerically flank-
ing beclin 1 is the WNK4 gene, known to regulate thia-
zide-sensitive Na-Cl co-transport [22], and the other
two genes, CNTD1 and CCDC56 with unknown func-
tions. Beclin gene is composed of 12 exons and exon
2 encodes the translational initial codon (ATG)
(Figure 5C). 5' region of the beclin 1 gene was
inspected by the MethPrimer program http://www.uro-
gene.org/methprimer. The data showed this region of
t h eg e n o m et ob eaC Gr i c h( F i g u r e5 D ) .T h eC p G
island encompassed from the promoter to the intron 2
(nt -528 to 977). Because aberrant cytosine methylation
within 5' end of tumor suppressor genes is commonly
observed in cancer cells [23,24], beclin 1 was likely a
candidate gene for epigenetic silencing.
Certain CpG dinucleotides in the promoter and the intron
2 of the beclin 1 gene were methylated in breast tumors
There are genetic and epigenetic alterations for the
down-regulation of many genes. To identify mutations
in the beclin 1 gene in breast cancer, mutational anlaysis
was carried out by PCR-SSCP in genomic DNA of 20
breast tumors. No mutation was found in 12 exons of
the beclin 1 gene in 20 breast tumors. As mentioned
above, there was a large and dense CpG island ranging
from the promoter to the intron 2 of the beclin 1 gene.
Therefore, we first detected the methylation status of
the CpG islands in the 6 breast tumors with significantly
down-regulated beclin 1 expression and corresponding
normal tissues by bisulfite sequencing. In the promoter
from -528 to -65 (from transcription start site) and the
intron 2 from 733 to 977, methylation was detected in
4 tumors (T3, 8, 16, 20) and weakly detected in the cor-
responding normal tissues. In the other two samples
(T1, 12) with significantly down-regulated beclin 1
expression and LOH, methylation was weakly detected
in both tumors and corresponding normal tissues. Then
we tested another 6 cases, whose beclin 1 mRNA
expression was not down-regulated in breast tumors,
and methylation was weakly or hardly detected in both
tumors and normal tissues (Figure 6).
Discussion
It has been reported that tumor suppressor genes with
high frequencies of LOH in human chromosomal region
17q21 and epigenetic silencing, are important in heredi-
tary and sporadic breast cancer tumorigenesis [25,26].
One of these genes is BRCA1, whose decreased expres-
sion was often observed in breast cancer with epigenetic
silencing and mono-allelic deletion of the BRCA1 gene
[27-29]. In the present study, we showed that the
mRNA and protein expression of beclin 1,a n o t h e r
17q21 gene, was frequently down-regulated in breast
tumors. This down-regulation in some tumors was due
to allele loss in gene copy number and in some others
was due to DNA methylation. There was no significant
association between beclin 1 mRNA expression and clin-
ocopathologic parameters.
P 5 3 ,B R C A 1a n dB R C A 2a r ec l e a r l yi n v o l v e di nt h e
development of both sporadic and hereditary breast can-
cers [30-34]. Mutations of these genes are the most
common genetic variations and are widely distributed in
breast cancer cells. Tumors with missense mutations
displayed positive nuclear immunoreactivity of p53 for
the effect of mutation on the prolongation of p53 half-
life through increased protein stability [35]. Cancers
with wild-type P53, including breast cancer [35], are
generally negative for p53 immunoreactivity due to the
rapid degradation of normal p53 protein. Meanwhile,
loss or reduction of BRCA1 and BRCA2 expression has
Table 4 Comparison between beclin 1 mRNA and protein
expression in breast cancer
Beclin 1 mRNA expression Beclin 1 protein expression (IHC)
(Quantitative RT-PCR) Positive Negative
Positive (6) 6 0
Negative (14) 1 13
p < 0.001
Positive means that the expression level of beclin 1 mRNA/protein in breast
tumors increased compared with the corresponding adjacent normal tissues.
And negative means that the expression level of beclin 1 mRNA/protein in
breast tumors decreased compared with the corresponding adjacent normal
tissues. The association between beclin 1 mRNA and protein expression was
analyzed using the c
2 test.
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Page 6 of 12Figure 3 P53, BRCA1 and BRCA2 staining in breast tumors. Signals were photographed in breast tissues at × 200. (A) Positive nuclear
staining of p53 protein; (B) No obvious nuclear staining was observed over the whole normal breast tissue; (C) Positive nuclear staining of
BRCA1 protein; (D) Negative control of BRCA1 staining in a breast tumor. (E) Positive nuclear staining of BRCA2 protein; (F) Negative control of
BRCA2 staining in a breast tumor.
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histochemistry of p53 and BRCA1/2 proteins in tumor
cells may be useful as an additional method in exploring
the relationship between the beclin 1 expression levels
and the status of these important tumor suppressor
genes in breast cancer. Therefore, we examined their
expression levels by immunohistochemcial staining in
20 breast tumors. By IHC staining of p53 protein, we
Table 5 Beclin 1 mRNA and protein expression, p53, BRCA1 and BRCA2 protein expression and LOH analysis of beclin
1 in breast cancer tissues
Breast cancer cases Beclin 1 mRNA expression Protein expression LOH (Q-PCR) LOH (microsatellite)
Beclin 1 P53 BRCA1 BRCA2
1- - - - - + +
2+ + - + + - -
3- - - - - + +
4- - - - + + - +
5+ + - + - - -
6- - - + + + +
7- - - + + + +
8- - - - - + +
9+ + - - - - -
10 - - - + - - -
11 + + + - + + +
12 - - - - - + +
13 - - - - + + +
14 - - - - - + +
15 + + - - - - -
16 - - - - - - -
17 + + + + + + -
18 - + - - - - -
19 - - - - + - -
20 - - - - + - -
“+": positive; “-": negative.
Table 6 Relationship between beclin 1 mRNA expression
and immunohistochemical characterization of p53,
BRCA1 and BRCA2 in breast IDCs
Case
number
Average of
log
Standard
deviation
P-
value
(%) T/N of log T/N
p53
Positive 2 (10) -0.24 0.24 0.798
Negative 18(90) -0.20 0.06
BRCA1
Positive 6 (30) -0.01 0.02 0.014*
Negative 14 (30) -0.31 0.08
BRCA2
Positive 9 (45) -0.16 0.04 0.483
Negative 11 (55) -0.24 0.10
No obvious nuclear p53 protein staining was defined as negative and over-
expression of p53 was defined as positive. Loss or reduction of BRCA1 and
BRCA2 expression was defined as negative in tumors compared with the
paired normal tissue, and vice versa.
Figure 4 Representative photograph showing LOH in breast
cancer. Above graph, microsatellite marker; under graph, patient’s
number; arrowheads, the allele losses; N, normal DNA; T, tumor
DNA.
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positive nuclear staining cells of all tumor cells. IHC
over-expression of p53 might reflect that genetic altera-
tions also occurred in these tumors. We further ana-
lyzed the correlation between beclin 1 expression and
p53 over-expression and no obvious association was
obtained. It is known that the normal BRCA1 protein
plays an important role in repairing breaks in DNA [37].
However, when BRCA1 exhibited loss of expression due
to genetic or epigenetic alterations, abnormal repair
function of BRCA1 may lead to DNA replication errors
and cancerous growth [38,39]. Liang et al [3] reported
that beclin 1 played a negative regulatory role in mam-
mary cell growth and tumorigenesis using gene-transfer
techniques. Our data showed that beclin 1 expression
was significant higher in the BRCA1 positive tumors
than in the negative ones, suggesting beclin 1 expression
may be related to cell growth in breast cancer.
Beclin 1 is mapped to a region approximately 150 kb
to BRCA1 on chromosome 17q21, which is usually
deleted in breast, ovarian and prostate cancer [8-11].
LOH at the beclin 1 locus was observed in 9 out 22
(41%) of the breast cancer cell lines [9]. In the present
study, all examined tumors exhibited a LOH rate of at
least 45% at the beclin 1 locus and no mutation was
found in the coding regions of beclin 1. These results
confirmed that frequent allelic losses of beclin 1 were
part of reasons for beclin 1 down-regulation and
Table 7 Comparison between microsatellite and
quantitative – PCR method for LOH analysis of the beclin
1 gene in 20 paired tissues
Q-PCR D17S579
Negative Positive
Positive (13) 2 11
Negative (7) 7 0
p < 0.001
D17S579 was a microsatellite marker located in 17q21. Comparison was
analyzed using the c
2 test.
Figure 5 Genomic architecture of the human beclin 1 gene. The genome database of National Center for Biotechnology Information (NCBI)
and MethPrimer program were used to inspect the beclin 1 locus and CpG island, respectively. (A) Location of the beclin 1 gene within human
chromosome 17. (B) 70-kb region flanking the beclin 1 gene and its relative location with neighbor genes. (C) Exon/intron structure of the
human beclin 1 gene. (D) Graph of percent guanine (G) and cytosine (C) nucleotides across 5' region of the beclin 1 gene and location of CpG
dinucleotides.
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for beclin 1 inactivation in breast cancer. Meanwhile,
allelic loss of beclin 1 was only found in a portion of the
breast tumors with down-regulated expression, indicat-
ing that mechanisms other than allelic deletion may be
responsible for the decrased mRNA expression.
The CpG island in beclin 1 spans over 1.5 kb from the
promoter to the intron 2 [nucleotide (nt) -528 to 977]
with the transcription start site defined as +1, so it is
divided into four regions to be cloned. The first region
contained part of the beclin 1 promoter from -528 to
-65. The second region was located between -83 and
164 from the proximal promoter to part of the first
Figure 6 Methylation status of beclin 1 gene in different cases. (A) Methylation patterns of the beclin 1 gene in breast tumors and adjacent
normal tissues. Sequencing of bisulfite treated DNA revealed methylation patterns for beclin 1 gene. Black squares represent methylated CpG
dinucleotides, white squares represent unmethylated CpG dinucleotides and gray squares are hemimethylated. Hemimethylated (grey squares)
means that only one C allele in the same CpG site of the two DNA strands is methylated. Methylated (dark squares) means that both C alleles in
the same CpG site of the two DNA strands are methylated and unmethylated means that both C alleles in the same CpG site of the two DNA
strands are unmethylated. 1, 3, 8, 12, 16 and 20: samples with significant decreased expression of beclin 1; 2, 5, 9, 11, 15 and 17: samples without
decreased expression of beclin 1 in tumors. (B) Percentage of methylation status from 1
st to 19
th CpG site in the promoter of beclin 1 in 6 cases
with significant decreased mRNA expression. (C) Percentage of methylation status from 1
st to 11
th CpG site in intron 2 of beclin 1 in 6 cases with
significant decreased mRNA expression.
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a portion of the first intron to part of the second exon.
The fourth region was situated between 733 and 977
from a portion of the second intron. We found that cer-
tain CpG dinucleotides at the promoter and the intron
2o ft h ebeclin 1 gene are hypermethylated in breast
tumors. As dense methylation of the 5' CpG islands was
not detected in normal tissues, we speculated that this
methylation patterns in tumor cells were aberrant and
disease associated. As a whole, the regulation of beclin 1
expression was a little complicated. In some cases, T16
and T20, the decreased expression was due to aberrant
DNA methylation; While in T1 and T12, the decrease
was from LOH; And in the other cases, T3 and T8,
both aberrant DNA methylation and LOH devoted to
the decreased expression of beclin 1 (Table 8). For this
reason, different mechanisms seemed to be involved in
the regulation of beclin 1 expression.
Some tumors (T10 and T19) with low expression of
beclin 1 did not have either LOH or methylation. Other
identified mechanisms might contribute to the regula-
tion of beclin 1 expression, such as bcl-2 overexpression
[40]. Recently, a novel beclin 1 binding protein,
UVRAG, was found to positively regulate autophagy sig-
naling pathway mediated by beclin 1 in colon cancer
[41]. Exploring different involving factors that could
affect the regulatory expression of beclin 1 might contri-
bute to the pathogenesis of human cancers.
Aberrant methylation of 5' CpG islands associated
with down-regulated mRNA expression of beclin 1 indi-
c a t e dt h a tm e t h y l a t i o nm i g h tb ean e wm e c h a n i s mf o r
loss of expression of beclin 1, which has not been
shown previously. Sequence analysis revealed that there
were four putative consensus Sp1 binding sites at the
promoter [17] and one putative Sp1 binding site at the
intron 2, which share high sequence homology to the
consensus Sp1 motif. It has been reported that aberrant
DNA hypermethylation in the promoter of a gene can
silence its expression [42], and that methylation in the
introns can silence or enhance its expression [43-45].
Whether DNA methylation in the promoter and the
intron 2 of beclin 1 affects the binding affinity of tran-
scriptional factor needs to be further determined.
Conclusions
In conclusion, our studies confirmed that down-regula-
tion of beclin 1 expression is present in breast cancer.
Other than deletion in gene copy number, DNA hyper-
methylation in the promoter and/or intron 2 may be a
new mechanism responsible for down-regulation of
beclin 1 expression. Since beclin 1 has important func-
tions in apoptosis and autophagy, its epigenetic modifi-
cation might provide new targets for cancer therapy.
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